Albutrepenonacog alfa

Drug Profile

Albutrepenonacog alfa

Alternative Names: CSL 640; CSL-654; Idelvion; Recombinant factor IX - CSL Behring; Recombinant factor IX fusion protein linked with human albumin; rFIX-FP - CSL Behring; rIX-FP

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator CSL Behring
  • Class Albumins; Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B
  • Clinical Phase Unknown Haemophilia

Most Recent Events

  • 28 Feb 2017 Clinical trials in Haemophilia (SC) before February 2017 (CSL group pipeline, February 2017)
  • 03 Dec 2016 Registered for Haemophilia B (In adolescents, In children, In adults) in Switzerland (IV) Before December 2016
  • 03 Dec 2016 Updated pooled results from the phase III PROLONG-9FP trials were presented at the 58th annual meeting of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top